TL;DR
This study suggests that neoadjuvant chemoimmunotherapy (NCIT) may offer better short-term survival for patients with locally advanced esophageal squamous cell carcinoma (ESCC) compared to the current standard of neoadjuvant chemoradiotherapy (NCRT). While both approaches yielded similar perioperative and pathological outcomes, NCIT demonstrated a significant improvement in 2-year overall survival and disease-free survival rates.
What Problem Does This Paper Address?
Esophageal squamous cell carcinoma (ESCC) remains a significant cause of cancer-related deaths globally. For locally advanced stages, treatment typically involves neoadjuvant therapy followed by surgery. Historically, neoadjuvant chemoradiotherapy (NCRT) has been the standard of care, showing improved survival rates compared to surgery alone. However, locoregional and distant recurrence remain significant challenges, prompting research into novel treatment strategies. The advent of immunotherapy has led to the investigation of neoadjuvant chemoimmunotherapy (NCIT) as a promising alternative. This paper aims to compare the efficacy and safety of NCIT versus NCRT in patients with locally advanced ESCC, specifically focusing on short-term survival and perioperative outcomes.
Methods
This retrospective study employed a propensity score matching (PSM) analysis to compare outcomes between two groups of patients with locally advanced ESCC: one receiving neoadjuvant chemoimmunotherapy (NCIT) and the other receiving neoadjuvant chemoradiotherapy (NCRT). The study included 214 patients treated between May 2014 and April 2022. PSM was used to create balanced cohorts (66 patients in each group) by accounting for various confounding factors such as age, sex, KPS score, smoking and drinking history, comorbidities, tumor location, and clinical T, N, and M stages. The researchers then compared perioperative findings, pathological results, and survival data between these matched groups. Key outcome measures included pathological complete response (pCR), major pathological response (MPR), operative time, blood loss, hospital stay, postoperative complications (including anastomotic leakage), and survival rates (overall survival and disease-free survival).
Datasets
The study utilized data from 214 patients treated at the Tianjin Medical University Cancer Institute and Hospital. This retrospective cohort was divided into two groups based on their neoadjuvant treatment: NCIT (n=78) and NCRT (n=136). After propensity score matching, the study focused on balanced cohorts of 66 patients in each group. No new datasets were introduced.
Key Insights and Ideas
- NCIT shows promise for short-term survival: The most striking finding is the superior short-term survival observed with NCIT compared to NCRT, particularly evident in the 2-year overall and disease-free survival rates. This suggests that immunotherapy, when combined with chemotherapy in the neoadjuvant setting, can offer a significant survival advantage.
- Similar perioperative and pathological outcomes: Despite the survival differences, NCIT and NCRT demonstrated comparable perioperative outcomes and pathological response rates (MPR and pCR). This indicates that NCIT is not only effective but also as safe as the current standard in terms of surgical and pathological results.
- Impact on lymph node dissection: The NCIT group had a significantly higher number of harvested lymph nodes compared to the NCRT group. This could be attributed to the potential for chemoradiotherapy to cause fibrosis, which may increase surgical difficulty and hinder lymph node dissection.
- Anastomotic leakage warrants attention: While overall postoperative complications were similar, there was a trend towards fewer anastomotic leakages in the NCIT group before matching, though this difference was not significant after matching. The discussion highlights that local radiation in NCRT might contribute to impaired healing in the anastomotic site.
Key Results
- Survival: After 1:1 PSM, the 2-year cumulative overall survival rates were 80.2% for the NCIT group and 62.2% for the NCRT group (p=0.029). Similarly, the 2-year cumulative disease-free survival rates were 70.0% for NCIT and 50.8% for NCRT (p=0.023).
- Pathological Response: The pathological complete response (pCR) rates were similar between the groups: 25.8% for NCIT and 27.3% for NCRT (p>0.05). Major pathological response (MPR) rates were also comparable.
- Lymph Nodes: The NCIT group had a significantly higher number of harvested lymph nodes (33.6 ± 12.7) compared to the NCRT group (21.7 ± 10.2) (p<0.001).
- Surgical Interval: The time between neoadjuvant therapy completion and surgery was significantly longer after NCRT (47.1 ± 13.2 days) than after NCIT (34.7 ± 8.8 days) (p<0.001).
- Complications: Overall postoperative complications and mortality rates did not differ significantly between the groups after matching.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective nature: This inherent limitation means that selection bias and multiplicity are potential concerns.
- Small sample size: The number of included patients, particularly in the NCIT group after matching, was relatively small.
- Short follow-up duration: The follow-up period was considered short, especially for the NCIT group, raising questions about long-term survival benefits.
Future work should focus on:
- Prospective controlled trials: To validate these findings and confirm whether the observed short-term survival benefits translate into long-term survival advantages.
- Evaluating diverse regimens: The study used various immuno- and chemo-regimens, and future research could standardize these or explore specific combinations.
- Robot-assisted surgery impact: Further investigation is needed to understand how advanced surgical techniques like robot-assisted esophagectomy might influence lymph node dissection and patient survival.
Summary updated